Etg Neuroscience Sp. z o.o.
- Address
- lock Available on a paid plan
ETG Neuroscience - Specialized Neurological and Pain Research Center
ETG Neuroscience Sp. z o.o. is a specialized clinical research center with extensive expertise in neurological disorders and pain management. The facility has established itself as a leader in conducting complex Phase 2 and Phase 3 clinical trials across a diverse range of therapeutic areas, with particular emphasis on central nervous system conditions and chronic pain syndromes.
- Parkinson's Disease research, including motor fluctuation treatments, tremor management, and disease-modifying therapies
- Migraine prevention and treatment studies, encompassing both episodic and chronic migraine in adult and pediatric populations
- Alzheimer's Disease and cognitive impairment clinical trials
- Chronic pain conditions, including low back pain, diabetic neuropathy, and specialized pain management approaches
The center demonstrates comprehensive capabilities in evaluating novel therapeutic approaches, from traditional pharmacological interventions to innovative biologics and disease-modifying treatments. Their research portfolio includes investigations of monoclonal antibodies, botulinum toxin preparations, extended-release formulations, and emerging treatment modalities. With additional experience in multiple sclerosis, allergic rhinitis, and hypertension trials, ETG Neuroscience provides a multidisciplinary approach to clinical research, supporting the development of next-generation therapies for patients with complex neurological and chronic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 147 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 145 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 32 by active trials.
lock +31 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +19 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Etg Neuroscience Sp. z o.o.
lock Showing 1 of 97 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE | UCB Biopharma | Phase II | Not Recruiting | Dec 2022 | Mar 2025 |
IMP list
lock Showing 1 of 147 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 6 | Unknown | 2024-05-07 | 2026-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.